Skip to main
WGS

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings is a rapidly growing market leader in rare-disease testing lab services, with expertise in whole-exome and whole-genome testing, particularly in children. The company's shift to focus on pediatric and rare-disease diagnostics positions it to capitalize on the growing demand for precision medicine and genetic diagnoses. With the recent acquisition of Fabric Genomics, GeneDx can expand its reach and potentially enter international markets, making it a strong and diversified player in the genomics industry.

Bears say

GeneDx Holdings is facing significant headwinds due to missed revenue expectations and decreased gross margin. The company's reliance on whole exome and genome sequencing, while potentially revolutionary, presents risks from reimbursement challenges and potential reluctance from geneticists to move from targeted gene panels. GeneDx is also facing pressure from competition and pricing in various segments, including in its core base NIPT market. Despite these challenges, the company's focus on rare pediatric diseases and potential for data monetization opportunities may provide future growth opportunities, but the near-term outlook is uncertain.

WGS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Strong Buy based on their latest research and market trends.

According to 5 analysts, WGS has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.